随机II期试验：具有误导性且不可靠。 - Suppr

Suppr

超能文献

Randomized phase II trials: misleading and unreliable.

作者信息

Stewart David J

出版信息

J Clin Oncol. 2010 Nov 1;28(31):e649-50; author reply e651-3. doi: 10.1200/JCO.2010.31.3254. Epub 2010 Sep 20.

DOI:10.1200/JCO.2010.31.3254

PMID:20855829

Abstract

摘要

相似文献

Randomized phase II trials: misleading and unreliable.

J Clin Oncol. 2010 Nov 1;28(31):e649-50; author reply e651-3. doi: 10.1200/JCO.2010.31.3254. Epub 2010 Sep 20.

Examining heterogeneity in phase II trial designs may improve success in phase III.

J Natl Cancer Inst. 2008 Feb 6;100(3):164-6. doi: 10.1093/jnci/djn006. Epub 2008 Jan 29.

Criticism of tumor response criteria raises trial design questions.

J Natl Cancer Inst. 2006 Feb 15;98(4):232-4. doi: 10.1093/jnci/djj086.

[Methodological approaches of clinical studies with targeted therapies].

Bull Cancer. 2008 Feb;95(2):185-90. doi: 10.1684/bdc.2008.0575.

Design and endpoints of clinical trials in hepatocellular carcinoma.

J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13.

Developing drugs that do not cause tumor regression.

Clin Adv Hematol Oncol. 2003 Nov;1(11):654-5.

Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?

J Natl Cancer Inst. 2007 Oct 3;99(19):1422-3. doi: 10.1093/jnci/djm167. Epub 2007 Sep 25.

Optimising the design of phase II oncology trials: the importance of randomisation.

Eur J Cancer. 2009 Jan;45(2):275-80. doi: 10.1016/j.ejca.2008.10.029. Epub 2008 Dec 6.

A strategic framework for novel drug development in multiple myeloma.

Br J Haematol. 2007 Jul;138(2):153-9. doi: 10.1111/j.1365-2141.2007.06641.x.

Optimizing randomized phase II trials assessing tumor progression.

Contemp Clin Trials. 2007 Feb;28(2):146-52. doi: 10.1016/j.cct.2006.05.003. Epub 2006 May 19.

引用本文的文献

An Overview of Phase 2 Clinical Trial Designs.

Int J Radiat Oncol Biol Phys. 2022 Jan 1;112(1):22-29. doi: 10.1016/j.ijrobp.2021.07.1700. Epub 2021 Aug 4.

A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials.

J Natl Cancer Inst. 2019 Dec 1;111(12):1255-1262. doi: 10.1093/jnci/djz126.

Do single-arm trials have a role in drug development plans incorporating randomised trials?

Pharm Stat. 2016 Mar-Apr;15(2):143-51. doi: 10.1002/pst.1726. Epub 2015 Nov 26.

Fool's gold, lost treasures, and the randomized clinical trial.

BMC Cancer. 2013 Apr 16;13:193. doi: 10.1186/1471-2407-13-193.

Designing phase II trials in cancer: a systematic review and guidance.

Br J Cancer. 2011 Jul 12;105(2):194-9. doi: 10.1038/bjc.2011.235. Epub 2011 Jun 28.

Randomized phase II trials: a long-term investment with promising returns.

J Natl Cancer Inst. 2011 Jul 20;103(14):1093-100. doi: 10.1093/jnci/djr218. Epub 2011 Jun 27.

More randomization in phase II trials: necessary but not sufficient.

J Natl Cancer Inst. 2011 Jul 20;103(14):1075-7. doi: 10.1093/jnci/djr238. Epub 2011 Jun 27.

Latest developments in the treatment of melanoma: 'a penicillin moment for cancer'?

J R Soc Med. 2011 Jun;104(6):269-72. doi: 10.1258/jrsm.2011.100405.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Randomized phase II trials: misleading and unreliable.

J Clin Oncol. 2010 Nov 1;28(31):e649-50; author reply e651-3. doi: 10.1200/JCO.2010.31.3254. Epub 2010 Sep 20.

Examining heterogeneity in phase II trial designs may improve success in phase III.

J Natl Cancer Inst. 2008 Feb 6;100(3):164-6. doi: 10.1093/jnci/djn006. Epub 2008 Jan 29.

Criticism of tumor response criteria raises trial design questions.

J Natl Cancer Inst. 2006 Feb 15;98(4):232-4. doi: 10.1093/jnci/djj086.

[Methodological approaches of clinical studies with targeted therapies].

Bull Cancer. 2008 Feb;95(2):185-90. doi: 10.1684/bdc.2008.0575.

Design and endpoints of clinical trials in hepatocellular carcinoma.

J Natl Cancer Inst. 2008 May 21;100(10):698-711. doi: 10.1093/jnci/djn134. Epub 2008 May 13.

Developing drugs that do not cause tumor regression.

Clin Adv Hematol Oncol. 2003 Nov;1(11):654-5.

Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?

J Natl Cancer Inst. 2007 Oct 3;99(19):1422-3. doi: 10.1093/jnci/djm167. Epub 2007 Sep 25.

Optimising the design of phase II oncology trials: the importance of randomisation.

Eur J Cancer. 2009 Jan;45(2):275-80. doi: 10.1016/j.ejca.2008.10.029. Epub 2008 Dec 6.

A strategic framework for novel drug development in multiple myeloma.

Br J Haematol. 2007 Jul;138(2):153-9. doi: 10.1111/j.1365-2141.2007.06641.x.

Optimizing randomized phase II trials assessing tumor progression.

Contemp Clin Trials. 2007 Feb;28(2):146-52. doi: 10.1016/j.cct.2006.05.003. Epub 2006 May 19.

引用本文的文献

An Overview of Phase 2 Clinical Trial Designs.

Int J Radiat Oncol Biol Phys. 2022 Jan 1;112(1):22-29. doi: 10.1016/j.ijrobp.2021.07.1700. Epub 2021 Aug 4.

A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials.

J Natl Cancer Inst. 2019 Dec 1;111(12):1255-1262. doi: 10.1093/jnci/djz126.

Do single-arm trials have a role in drug development plans incorporating randomised trials?

Pharm Stat. 2016 Mar-Apr;15(2):143-51. doi: 10.1002/pst.1726. Epub 2015 Nov 26.

Fool's gold, lost treasures, and the randomized clinical trial.

BMC Cancer. 2013 Apr 16;13:193. doi: 10.1186/1471-2407-13-193.

Designing phase II trials in cancer: a systematic review and guidance.

Br J Cancer. 2011 Jul 12;105(2):194-9. doi: 10.1038/bjc.2011.235. Epub 2011 Jun 28.

Randomized phase II trials: a long-term investment with promising returns.

J Natl Cancer Inst. 2011 Jul 20;103(14):1093-100. doi: 10.1093/jnci/djr218. Epub 2011 Jun 27.

More randomization in phase II trials: necessary but not sufficient.

J Natl Cancer Inst. 2011 Jul 20;103(14):1075-7. doi: 10.1093/jnci/djr238. Epub 2011 Jun 27.

Latest developments in the treatment of melanoma: 'a penicillin moment for cancer'?

J R Soc Med. 2011 Jun;104(6):269-72. doi: 10.1258/jrsm.2011.100405.